Koselugo (Selumetinib)
- Medicine Name: Koselugo
- Generic Name: Selumetinib
- Dosage Form & Strength: Capsules: 10mg/25mg
- Manufactured By: AstraZeneca and MSD, Inc.
Koselugo is a kinase inhibitor used for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Recommended Dosage: The recommended dosage is 25 mg/m2 orally twice daily (around every 12 hours) until the disease is progressive or unacceptable toxicity. Take koselugo capsules on an empty stomach. Avoid consuming food 2 hours prior to each dose or 1 hour after each dose. Swallow the capsules whole with water. Avoid chewing, dissolving or opening of the capsule. Do not take a missed dose unless it is beyond 6 hours until the next scheduled dose. In case vomiting occurs after capsules administration, do not take an additional dose, but carry on with the next scheduled dose.
- Assess ejection fraction by echocardiogram prior to starting treatment, every three months during the first year of treatment, every six months thereafter.
- In patients who interrupt therapy with koselugo 25 mg for reduced LVEF, obtain an echocardiogram or a cardiac MRI every 3-6 weeks.
- Serious ocular toxicities including retinal pigment epithelial detachment (RPED) and retinal vein occlusion (RVO), occurred in an unapproved group of adult patients with multiple tumor types who received selumetinib capsules as a single agent or along with other anti-cancer agents.
- Comprehensive ophthalmic assessments need to be conducted before initiating treatment with selumetinib, at regular intervals during therapy, and for new/worsening visual changes.
- Severe gastrointestinal toxicities, including ileus, perforation, colitis, and intestinal obstruction, occurred in an unapproved group of adult patients with multiple tumor types who received selumetinib 25 mg capsules as a single agent or along with other anti-cancer agents.
- Diarrhea occurred in pediatric patients who received selumetinib. Patients should start an anti-diarrheal agent immediately after the first episode of unformed, loose stool and to increase fluid intake during the episodes of diarrhea.
- Rash occurred in pediatric patients who received selumetinib. Monitor for serious skin rashes. Withhold, reduce dose, or permanently interrupt koselugo 10 mg based on the severity of adverse reaction.
- Other skin toxicities, including severe palmar-plantar erythrodysesthesia syndrome, appeared in an unapproved group of adult patients with multiple tumor types who received capsules of koselugo as a single agent or along with other anti-cancer agents.
- Serum CPK should be obtained prior to initiating selumetinib 10 mg, periodically during treatment. In case increased CPK occurs, assess patients for rhabdomyolysis or other causes.
- Bleeding may occur in those patients who are co-administered vitamin-K antagonists or anti-platelet antagonists with selumetinib treatment. Patients should be monitored for bleeding.
- Findings from animal studies and mechanism of action suggest that selumetinib can cause fetal harm if administered to a pregnant woman.
What documents are required to import KOSELUGO to India?
KOSELUGO (Selumetinib) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation needed in order to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is KOSELUGO available in India?
KOSELUGO (selumetinib capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
KOSELUGO can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of KOSELUGO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for koselugo price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the KOSELUGO (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Koselugo®?
Selumetinib is Generic Name for the trade name drug Koselugo®.
What is the Manufacturer Name of Koselugo®?
Koselugo® is manufactured by AstraZeneca and MSD, Inc.
Is Koselugo® approved by the FDA?
Yes, Koselugo® is approved by the FDA. Date of approval: April 10, 2020.
What is Koselugo®?
Koselugo® (Selumetinib) is the first and only prescription medicine approved by FDA that is used to treat children aged 2 years and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely eliminated by surgery.
What is the dosage and form of Koselugo® supplied?
Koselugo® is supplied as Capsules: 10 mg and 25 mg for oral administration.
What are the most common side effects due to Koselugo®?
Most common side effects due to Koselugo® include: dry skin, vomiting, rash, abdominal pain, diarrhea, nausea, fatigue, acneiform rash, musculoskeletal pain, pyrexia, stomatitis, paronychia, headache, and pruritus.
How much does Selumetinib cost in India?
The selumetinib cost in India is absolutely reasonable. In order to procure this neurofibromatosis type-1 medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Koselugo®?
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense in the original bottle. Do not eliminate desiccant. Protect capsules from moisture.
What are the Highlights of prescribing information for Koselugo®?
Click Here to download full Koselugo prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.